Liver Cancer

COX-2 May Be Marker For Differentiation

Published in Cancer Weekly, June 12th, 2001

by Sonia Nichols, senior medical writer - A Korean study shows differentiated liver cancer cells significantly express COX-2 (cyclooxygenase-2), suggesting a potential use for COX-2 inhibitors in fighting this disease.

Primary liver cancer, also known as hepatocellular carcinoma (HCC), is one of the most common forms of cancer in the world, particularly in regions of viral hepatitis endemicity. The results of this study, which show the protein complex COX-2 is upregulated in well-differentiated HCC, may mean patients with certain types of HCC could some day be treated with COX-2 inhibitors, which are already being used to treat other illnesses.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2001-06-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry